CASI Pharmaceuticals Receives Nasdaq Delisting Decision; Shares to be Suspended

summarizeSummary

CASI Pharmaceuticals announced it has received a delisting decision from Nasdaq, with trading to be suspended on February 26, 2026, and the company expects to move to the OTC market.

check_boxKey Events

• Nasdaq Delisting Decision Received

  CASI Pharmaceuticals received a determination letter from the Nasdaq Hearings Panel notifying the company of its decision to delist the company's securities.

• Trading Suspension Imminent

  The company's securities will be suspended from trading at the open of business on February 26, 2026, and subsequently delisted from Nasdaq.

• No Appeal Intended

  CASI Pharmaceuticals does not intend to request a review of the Nasdaq Panel's delisting decision.

• Transition to OTC Market Expected

  Following delisting, the company expects its ordinary shares to be quoted on the 'over the counter' market operated by OTC Markets Group Inc.

auto_awesomeAnalysis

CASI Pharmaceuticals has received a definitive delisting decision from Nasdaq, effective February 26, 2026. This is a critical event that will significantly impact the company's stock liquidity and investor accessibility, as trading will move to the less regulated OTC market. The company's decision not to appeal suggests this outcome was anticipated or unavoidable, following a period of compliance issues. This news comes after recent efforts to secure financing and a significant investor taking an executive role, indicating ongoing challenges for the company, especially after the recent non-approval of a key drug license in China. While the company states the delisting will not impact operations, the market typically views such events negatively due to reduced visibility and institutional investment.